Skip to main content
. 2016 Sep;11(9):1511–1521. doi: 10.1016/j.jtho.2016.05.028

Table 3.

Best Overall Tumor Response in the Efficacy Population (n = 38)

Tumor response Value
RECIST version 1.0
 Complete response 1 (3.4%)
 Partial response 20 (69.0%)
 Stable disease 3 (10.3%)
 Progressive disease 5 (17.2%)
 Not assessed/missing 9
Immune-related response criteria
 Complete response 2 (6.1%)
 Partial response 26 (78.8%)
 Stable disease 5 (15.2%)
 Progressive disease 0
 Not assessed/missing 5

RECIST, Response Evaluation Criteria in Solid Tumors.